Emergent BioSolutions files for IPO
Gazette Newswatch
Anthrax vaccine maker Emergent BioSolutions of Gaithersburg has filed for its initial public offering, largely to raise funds for developing several of its other products, according to a company filing this week with the U.S. Securities and Exchange Commission.
The company manufactures and markets BioThrax, the only anthrax vaccine approved by the U.S. Food and Drug Administration, to federal agencies such as the Pentagon and the Department of Health and Human Services, said company spokesman Robert G. Burrows. Burrows said the company is not yet disclosing the number of shares or prices in the IPO.
Revenues from BioThrax sales were $55.5 million in 2003, $81.0 million in 2004 and $127.3 million in 2005. However, the company expressed concerns in its SEC report that its federal contracts are not guaranteed and competition is increasing from other companies.
Anthrax vaccine maker Emergent BioSolutions of Gaithersburg has filed for its initial public offering, largely to raise funds for developing several of its other products, according to a company filing this week with the U.S. Securities and Exchange Commission.
The company manufactures and markets BioThrax, the only anthrax vaccine approved by the U.S. Food and Drug Administration, to federal agencies such as the Pentagon and the Department of Health and Human Services, said company spokesman Robert G. Burrows. Burrows said the company is not yet disclosing the number of shares or prices in the IPO.
Revenues from BioThrax sales were $55.5 million in 2003, $81.0 million in 2004 and $127.3 million in 2005. However, the company expressed concerns in its SEC report that its federal contracts are not guaranteed and competition is increasing from other companies.
